Shares of Celgene Corp. dived 8 percent after a major shareholder in Bristol-Myers Squibb Co. came out against a $74 billion merger that would be the pharmaceutical world’s largest-ever takeover.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
In seeking innovative players that could change pharma and healthcare, Med Ad News found the developer of an app that helps people determine what illnesses are in their neighborhoods; the creator of a wearable injector that allows patients on biologics to receive these drugs outside the clinic; and a designer of a deep learning network aimed at giving pharma and healthcare companies a handle on their data.
The top performers of the launch class of 2016 have very little in common – aside from the fact that none of them came from a “classic” big pharma house.
Mylan NV shares slid 10 percent after the generic drug maker predicted poor 2019 earnings that led some Wall Street analysts to wonder if the company’s finances would worsen further.
Sarepta Therapeutics will buy privately held gene therapy company Myonexus Therapeutics for $165 million, moving deeper into an emerging and lucrative field within the biotech sector.
Bausch Health Companies Inc. was selected as the successful bidder to acquire certain assets of Synergy Pharmaceuticals Inc. for a cash purchase price of approximately $195 million and the assumption of certain assumed liabilities, pursuant to the terms of the stalking horse asset purchase agreement previously entered into.
Democrats in the U.S. House of Representatives unveiled an ambitious proposal to move all Americans into the government’s Medicare health insurance program.
Morris Plains, N.J.-based Immunomedics announced that the company’s president, chief executive officer and board member, Michael Pehl, was stepping down for personal reasons.
Amicus Therapeutics – with headquarters in Cranbury, New Jersey – announced that the company is launching a Global Research and Gene Therapy Center of Excellence in Philadelphia.
U.S. Senators called drug pricing practices “morally repugnant” and told drug company executives they do not want to hear them blame others for the high prices, taking an aggressive stance at the start of a Senate hearing on the rising costs of prescription medicines.
Benchworks Inc. announced the formation of BW Health Group, an integrated healthcare company led by Tom McDonnell.
EVERSANA announced three appointments to the company’s executive leadership team.